416 related articles for article (PubMed ID: 16785393)
1. Cutaneous manifestations of visceral leishmaniasis resistant to liposomal amphotericin B in an HIV-positive patient.
Alsina-Gibert M; López-Lerma I; Martinez-Chamorro E; Herrero-Mateu C
Arch Dermatol; 2006 Jun; 142(6):787-9. PubMed ID: 16785393
[No Abstract] [Full Text] [Related]
2. An HIV-positive man with tattoo induration.
López-Medrano F; Costa JR; Rodriguez-Peralto JL; Aguado JM
Clin Infect Dis; 2007 Jul; 45(2):220-1, 267-8. PubMed ID: 17578782
[No Abstract] [Full Text] [Related]
3. Cutaneous leishmaniasis associated with visceral leishmaniasis in a case of acquired immunodeficiency syndrome (AIDS).
Pourahmad M; Hooshmand F; Rahiminejad M
Int J Dermatol; 2009 Jan; 48(1):59-61. PubMed ID: 19126052
[TBL] [Abstract][Full Text] [Related]
4. Gastric and cutaneous dissemination of visceral leishmaniasis in a patient with advanced HIV.
Balkhair A; Ben Abid F
Int J Infect Dis; 2008 Jan; 12(1):111-3. PubMed ID: 17643333
[No Abstract] [Full Text] [Related]
5. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
[TBL] [Abstract][Full Text] [Related]
6. Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.
Borrelli P; Imperato A; Murdaca G; Scudeletti M
Ann Ital Med Int; 2000; 15(2):169-71. PubMed ID: 10920508
[TBL] [Abstract][Full Text] [Related]
7. [Visceral leishmaniasis in patient with HIV infection].
Olea P; Pinilla J
Rev Chilena Infectol; 2013 Apr; 30(2):216-20. PubMed ID: 23677161
[TBL] [Abstract][Full Text] [Related]
8. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
[TBL] [Abstract][Full Text] [Related]
9. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
Manfredi R; Marinacci G; Calza L; Passarini B
Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
[No Abstract] [Full Text] [Related]
10. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A
Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510
[TBL] [Abstract][Full Text] [Related]
11. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
[TBL] [Abstract][Full Text] [Related]
12. Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure--a case report and brief review of the literature.
Rybniker J; Goede V; Mertens J; Ortmann M; Kulas W; Kochanek M; Benzing T; Arribas JR; Fätkenheuer G
Int J Infect Dis; 2010 Jun; 14(6):e522-5. PubMed ID: 19726213
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
[TBL] [Abstract][Full Text] [Related]
14. Acute renal failure due to visceral leishmaniasis by Leishmania infantum successfully treated with a single high dose of liposomal amphotericin B.
Beltrame A; Arzese A; Camporese A; Rorato G; Crapis M; Tarabini-Castellani G; Boscutti G; Pizzolitto S; Calianno G; Matteelli A; Di Muccio T; Gramiccia M; Viale P
J Travel Med; 2008; 15(5):358-60. PubMed ID: 19006511
[TBL] [Abstract][Full Text] [Related]
15. Successful therapeutic splenectomy in an HIV patient with relapsing visceral leishmaniasis.
Alon D; Chowers M
Int J STD AIDS; 2012 Apr; 23(4):289-90. PubMed ID: 22581957
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of visceral leishmaniasis with liposomal amphotericin B.
Lagler H; Matt U; Sillaber C; Winkler S; Graninger W
Acta Biomed; 2006; 77 Suppl 2():22-5. PubMed ID: 16918063
[TBL] [Abstract][Full Text] [Related]
17. Clinical problem-solving. Where are you from?
Katz KC; Walmsley SL; McLeod AG; Keystone JS; Detsky AS
N Engl J Med; 2002 Mar; 346(10):764-7. PubMed ID: 11882733
[No Abstract] [Full Text] [Related]
18. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.
Davidson RN; Di Martino L; Gradoni L; Giacchino R; Russo R; Gaeta GB; Pempinello R; Scott S; Raimondi F; Cascio A
Q J Med; 1994 Feb; 87(2):75-81. PubMed ID: 8153291
[TBL] [Abstract][Full Text] [Related]
19. Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS.
Calza L; D'Antuono A; Marinacci G; Manfredi R; Colangeli V; Passarini B; Orioli R; Varoli O; Chiodo F
J Am Acad Dermatol; 2004 Mar; 50(3):461-5. PubMed ID: 14988693
[TBL] [Abstract][Full Text] [Related]
20. [The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection].
Delgado Fernández M; García Ordoñez MA; Martos Pérez F; Reguera Iglesias JM; Jiménez Oñate F; Colmenero Castillo JD
An Med Interna; 1997 Oct; 14(10):506-10. PubMed ID: 9424140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
